American Journal of Kidney Diseases
Volume 50, Issue 2 , Pages 305-313 , August 2007

Serum Vitamin E and Oxidative Protein Modification in Hemodialysis: A Randomized Clinical Trial

  • Liang Lu, PhD

      Affiliations

    • Department of Chemistry, Case Western Reserve University, Cleveland, OH
    • ,
  • Penny Erhard, BS

      Affiliations

    • Department of Medicine, Case Western Reserve University, Cleveland, OH
    • ,
  • Robert G. Salomon, PhD

      Affiliations

    • Department of Chemistry, Case Western Reserve University, Cleveland, OH
    • ,
  • Miriam F. Weiss, MD

      Affiliations

    • Department of Pathology, Case Western Reserve University, Cleveland, OH.
    • Corresponding Author InformationAddress correspondence to Miriam F. Weiss, MD, Renal Replacement LLC, 5096 Dogwood Trail, Lyndhurst, OH 44124.

Received 4 December 2006 ,Accepted 10 May 2007.

References 

  1. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med. 1993;328:1450–1456
  2. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione Trial. Lancet. 1999;354:447–455
  3. Lonn E, Bosch J, Yusuf S, et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: A randomized controlled trial. JAMA. 2005;293:1338–1347
  4. Halliwell B. The antioxidant paradox. Lancet. 2000;355:1179–1180
  5. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002;62:1524–1538
  6. Islam KN, O’Byrne D, Devaraj S, Palmer B, Grundy SM, Jialal I. Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy. Atherosclerosis. 2000;150:217–224
  7. Roob JM, Khoschsorur G, Tiran A, Horina JH, Holzer H, Winklhofer-Roob B. Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol. 2000;11:539–549
  8. Boaz M, Smetana S, Weinstein T, et al. Secondary Prevention with Antioxidants of Cardiovascular disease in End stage renal disease (SPACE): Randomised placebo-controlled trial. Lancet. 2000;356:1213–1218
  9. Stephens N, Parsons A, Shofield P, et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996;347:781–786
  10. Landmesser U, Harrison DG, Drexler H. Oxidant stress—A major cause of reduced endothelial nitric oxide availability in cardiovascular disease. Eur J Clin Pharmacol. 2006;62(suppl 13):S13–S19
  11. Ghiadoni L, Cupisti A, Huang Y, et al. Endothelial dysfunction and oxidative stress in chronic renal failure. J Nephrol. 2004;17:512–519
  12. Witting PK, Upston JM, Stocker R. The molecular action of alpha-tocopherol in lipoprotein lipid peroxidation (Pro- and antioxidant activity of vitamin E in complex heterogeneous lipid emulsions). Subcell Biochem. 1998;30:345–390
  13. Weiss M, Erhard P, Kader-Attia F, et al. Mechanisms for the formation of advanced glycation end products (AGEs) in end stage renal disease (ESRD). Kidney Int. 2000;57:2571–2585
  14. Salomon R, Kaur K, Batyreva E. Isolevuglandin-protein adducts in oxidized low density lipoprotein and human plasma: A strong connection with cardiovascular disease. Trends Cardiovasc Med. 2000;10:53–59
  15. Salomon R, Kaur K, Podrez E, Hoff H, Krushinsky A, Sayre L. HNE-derived 2-pentylpyrroles are generated during oxidation of LDL, are more prevalent in blood plasma from patients with renal disease or atherosclerosis, and are present in atherosclerotic plaques. Chem Res Toxicol. 2000;13:557–564
  16. Ikizler T, Moroz J, Roberts L, et al. Plasma F2-isprostanes levels are elevated in chronic hemodialysis patients. Clin Nephrol. 2002;58:190–197
  17. Siems W, Quast S, Peter D, et al. Oxysterols are increased in plasma of end-stage renal disease patients. Kidney Blood Press Res. 2005;28:302–306
  18. Sommerburg O, Zang L-Y, van Kuijk F. Simultaneous detection of carotenoids and vitamin E in human plasma. J Chromatogr B. 1997;695:209–215
  19. Friedlander M, Wu Y, Elgawish A, Monnier V. Early and advanced glycosylation end products: Kinetics of formation and clearance in peritoneal dialysis. J Clin Invest. 1996;97:728–735
  20. Salomon RG, Sha W, Brame C, et al. Protein adducts of iso[4]levuglandin E2, a product of the isoprostane pathway, in oxidized low density lipoprotein. J Biol Chem. 1999;274:20271–20280
  21. Girndt M, Lengler S, Kaul H, Sester U, Sester M, Kohler H. Prospective crossover trial of the influence of vitamin-E coated dialyzer membranes on T-cell activation and cytokine induction. Am J Kidney Dis. 2000;35:95–104
  22. Schwing W, Erhard P, Hollamon C, et al. Thrombotic events and markers of oxidation and inflammation in hemodialysis. Hemodialysis Int. 2004;8:338–343
  23. Himmelfarb J, Kane J, McMonagle E, et al. Alpha and gamma tocopherol metabolism in healthy subjects and patients with end-stage renal disease. Kidney Int. 2003;64:978–991
  24. Smith KS, Lee CL, Ridlington JW, Leonard SW, Devaraj S, Traber MG. Vitamin E supplementation increases circulating vitamin E metabolites tenfold in end-stage renal disease patients. Lipids. 2003;38:813–819
  25. Galli F, Buoncristiani U, Conte C, Aisa C, Floridi A. Vitamin E in uremia and dialysis patients. Ann N Y Acad Sci. 2004;1031:348–351
  26. Handelman GJ, Epstein WL, Peerson J, Spiegelman D, Machlin LJ, Dratz EA. Human adipose alpha-tocopherol and gamma-tocopherol kinetics during and after 1 y of alpha-tocopherol supplementation. Am J Clin Nutr. 1994;59:1025–1032
  27. Saldeen T, Li D, Mehta JL. Differential effects of alpha- and gamma-tocopherol on low-density lipoprotein oxidation, superoxide activity, platelet aggregation and arterial thrombogenesis. J Am Coll Cardiol. 1999;34:1208–1215
  28. Burton GW, Ingold KU. Autoxidation of biological molecules (1. The antioxidant activity of vitamin E and related chain-breaking phenolic antioxidants in vitro). J Am Chem Soc. 1981;103:6472–6477
  29. Yamauchi R, Ozaki K, Shimoyamada M, Kato K. Iron-catalyzed reaction products of alpha-tocopherol with 1-palmitoyl-2-linoleoyl-3-sn-phosphatidylcholine (13S)-hydroperoxide. Chem Phys Lipids. 2002;114:193–201
  30. Yamauchi R, Yagi Y, Kato K. Oxidation of alpha-tocopherol during the peroxidation of dilinoleoylphosphatidylcholine in liposomes. Biosci Biotechnol Biochem. 1996;60:616–620
  31. Zhang R, Brennan ML, Shen Z, et al. Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. J Biol Chem. 2002;277:46116–46122
  32. Poliakov E, Brennan ML, Macpherson J, et al. Isolevuglandins, a novel class of isoprostenoid derivatives, function as integrated sensors of oxidant stress and are generated by myeloperoxidase in vivo. FASEB J. 2003;17:2209–2220
  33. Brennan ML, Hazen SL. Amino acid and protein oxidation in cardiovascular disease. Amino Acids. 2003;25:365–374
  34. Christen S, Woodall A, Shigenaga M, Southwell-Keely P, Duncan M, Ames B. G-Tocopherol traps mutagenic electrophiles such as NOx and complements a-tocopherol: Physiological implications. Proc Natl Acad Sci U S A. 1997;94:3217–3222
  35. Jiang Q, Elson-Schwab I, Courtemanche C, Ames BN. Gamma-tocopherol and its major metabolite, in contrast to alpha-tocopherol, inhibit cyclooxygenase activity in macrophages and epithelial cells. Proc Natl Acad Sci U S A. 2000;97:11494–11499
  36. Devaraj S, Jialal I. Failure of vitamin E in clinical trials: Is gamma-tocopherol the answer?. Nutr Rev. 2005;63:290–293
  37. Himmelfarb J, Hakim RM. Oxidative stress in uremia. Curr Opin Nephrol Hypertens. 2003;12:593–598
  38. Wanner C, Bahner U, Mattern R, Lang D, Passlick-Deetjen J. Effect of dialysis flux and membrane material on dyslipidaemia and inflammation in haemodialysis patients. Nephrol Dial Transplant. 2004;19:2570–2575
  39. Baragetti I, Furiani S, Vettoretti S, et al. Role of vitamin E-coated membrane in reducing advanced glycation end products in hemodialysis patients: A pilot study. Blood Purif. 2006;24:369–376
  40. Odetti P, Traverso N, Monacelli F, et al. Vitamin E-coated filter decreases levels of free 4-hydroxyl-2-nonenal during haemodialysis sessions. Free Radic Res. 2006;40:207–212

 Originally published online as doi:10.1053/j.ajkd.2007.05.001 on June 28, 2007.

PII: S0272-6386(07)00793-7

doi: 10.1053/j.ajkd.2007.05.001

American Journal of Kidney Diseases
Volume 50, Issue 2 , Pages 305-313 , August 2007

Article Tools

* Image Usage & Resolution